Seneca Biopharma Inc fka SNCA

[Seel]

Results of this ph2 important. It is likely that the company will be able to further refine its targeted population for this treatment. Boatloads of data to sift thru and their statisticians will be earning every penny. We know nonbulbar. We know early, early. We'll know more later. When they are able to better refine parameters for target pop - they will have a beneficial treatment for that segment of the ALS population. Results of this study are good but the investment community wanted better identification of population who are treatment appropriate. We'll get that. That is a big part of what a phase 2 study does, and before they begin ph3, they will have parsed carefully and will have tighter parameters for their surgical patients than they did for this phase. There is nothing I can find to complain about with todays release. The results of this ph2 are exciting. The treatment helps a subset of ALS sufferers significantly. Garr's Barclay presentation today may offer us more details.